Experts See Positive Future For South Korean Biomedicine
This article was originally published in PharmAsia News
Biomedical experts in South Korea believe the outlook for the future of the biotechnology industry in the country is a positive one. The country currently has only a 4 percent share of the world biomedicine market, which is growing at the rate of 13 percent a year. Seoul National University has been one of five institutions around the world working on sequencing the DNA of the local males and females. South Korea's first biomedicine, an antibiotic, now has a $52.9 billion export contract. (Click here for more
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.